A case of advanced driver gene-negative NSCLC achieved imaging-confirmed complete response following anti-PD-L1 antibody (atezolizumab) therapy after progression on anti-PD-1 (nivolumab) treatment (38). This evidence concerns the gene CD274 and non-small cell lung carcinoma.